Lyell Immunopharma (LYEL): Chief Scientific Officer sold

~$1.4K
Approx. value · 131 sh @ $10.53: 9,093
Holds after · shares reported

Traded: Aug 11, 2025
Filed: Aug 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Aug 11, 2025 · this disclosureInsiderOfficer sold ~$1.4K of LYEL shares in the open market

What came next

Aug 11, 2025Insider · 3 peopleInsiders: 3 sales (~$6K)
Aug 12, 2025Insider · 4 peopleInsiders: 4 sales (~$8K)
Aug 21, 2025Insider · 4 peopleInsiders: 4 sales (~$118K)
Sep 15, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 15, 2025, Charles Newton notified Lyell Immunopharma, Inc. (the “Company”) of his decision to resign from his position as the Chief Financial Officer and principal financial and accounting officer of the Company, effective October 31, 2025 (the “Resignation Date”).”
Oct 31, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 31, 2025, the Board of Directors of Lyell Immunopharma, Inc. (the “Company”) appointed Lynn Seely, M.D., the Company’s President, Chief Executive Officer and principal executive officer and a director of the Company, as the Company’s interim principal financial officer, and appointed Veronica Sanchez Bulis, the Company’s Vice President, Corporate Controller, as the Company’s principal accounting officer.”
Nov 6, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
Dec 3, 2025Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lyell Immunopharma

OQRO holds no insider, Congress, fund or contract record for Lyell Immunopharma dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LYEL page.

Other recent filings by Gary K. Lee, Chief Scientific Officer

The full history of Gary K. Lee, Chief Scientific Officer is on the profile page.

Other disclosures at Lyell Immunopharma

Everything OQRO holds on this company is on its LYEL page.

Lyell Immunopharma (LYEL)Chief Scientific Officer sold ~$1.4K